TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06800391

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day
Description: Capecitabine (1250 mg/m2 /day) and Cyclophosphamide (50 mg/day) continuous daily dosing. Cycles are to be repeated every 28 days for a total of 6 cycles.
Study: NCT06801080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthySteps (https://www.zerotothree.org/our-work/healthysteps/)
Description: Within the DoD, most elements of the civilian HS model copyrighted by ZeroToThree.org were implemented. However, there were some modifications to accommodate the unique environment of the military community. The pilot utilized the pre-existing Military Family Life Counseling Program (MFLC) staff to serve as HS Specialists at participating clinics. MFLCs were hired and trained in the HS model through the HS Institute provided by ZeroToThree.org. Although the DoD pilot offered all 3 tiers of targeted care standard for the HS model, note that the DoD pilot did not offer a 24-hour parent support line at tier 1. Also, the DoD pilot required participating pilot clinics to utilize a modified version of the Tufts Survey of Well-Being of Young Children (SWYC; https://www.tuftsmedicine.org/medical-professionals-trainees/academic-departments/department-pediatrics/survey-well-being-young-children) to provide augmented screenings for infants at all tiers of pilot service provision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The comparison clinics included in this intervention were selected to represent pediatric care within military treatment facilities throughout the DHA medical system located at Army, Navy, Marine Corps, and Air Force facilities. There is variability in pediatric practice across military service branches. However, all clinics follow the American Academy of Pediatrics Bright Futures guidelines.
Study: NCT06800729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06800469

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbiota analysis
Description: Upon acquisition of informed consent, fecal, digiunal mucosa, biliary and pancreatic fluid samples will be collected for microbiota analysis
Study: NCT06800482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online outpatient follow-up
Description: The investigators use Huayitong APP for the post-operating follow-up of participants with papillary thyroid cancer
Study: NCT06801574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: After the surgical team places the final suture, while the patient is in the prone position, an ultrasound-guided ESP (Erector Spinae Plane) block will be administered bilaterally using a block needle. A total of 40 mL of 0.25% bupivacaine will be injected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infiltration
Description: Before the surgical team closes the incision, local infiltration with 40 mL of 0.25% bupivacaine will be performed at the surgical site.
Study: NCT06801327

Intervention type: DEVICE
Group type: OTHER
Intervention: Simeox
Description: The Investigators chose to evaluate this device for respiratory physiotherapy in our patients because it is the only one that offers innovative technology, as, unlike other commercially available devices, it does not require the patient to perform forced breathing. Instead, the patient can exhale calmly at tidal volume. This is expected to reduce the patient's effort and improve compliance with treatment. Furthermore, the vibratory signal with small, rapid, and sequential depressions within the airways could be more effective in mobilizing mucus from the airways, preventing collapse.

Intervention type: DEVICE
Group type: OTHER
Intervention: Simeox
Description: The Investigators chose to evaluate this device for respiratory physiotherapy in our patients because it is the only one that offers innovative technology, as, unlike other commercially available devices, it does not require the patient to perform forced breathing. Instead, the patient can exhale calmly at tidal volume. This is expected to reduce the patient's effort and improve compliance with treatment. Furthermore, the vibratory signal with small, rapid, and sequential depressions within the airways could be more effective in mobilizing mucus from the airways, preventing collapse.
Study: NCT06800560

Intervention type: OTHER
Intervention: MenoScale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: MenoScale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: MenoScale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: MenoScale
Description: Menopause symptom questionnaire
Study: NCT05095974

Intervention type: DEVICE
Intervention: echocardiography
Description: MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
Study: NCT06800560

Intervention type: OTHER
Intervention: Greene Climacteric Scale
Description: Menopause symptom questionnaire
Study: NCT06800560

Intervention type: OTHER
Intervention: Greene Climacteric Scale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: Greene Climacteric Scale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: Greene Climacteric Scale
Description: Menopause symptom questionnaire

Intervention type: OTHER
Intervention: RAND 36-Item Health Survey 1.0
Description: Quality of life questionnaire

Intervention type: OTHER
Intervention: RAND 36-Item Health Survey 1.0
Description: Quality of life questionnaire
Study: NCT05885204

Intervention type: PROCEDURE
Intervention: Robot-assisted radical cystectomy
Description: Robot-assisted laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Robot-assisted radical cystectomy
Description: Robot-assisted laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy
Study: NCT05095974

Intervention type: DEVICE
Intervention: thoracic electrical bioimpedence
Description: EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.

Intervention type: DEVICE
Intervention: thoracic electrical bioimpedence
Description: EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
Study: NCT06800560

Intervention type: OTHER
Intervention: RAND 36-Item Health Survey 1.0
Description: Quality of life questionnaire

Intervention type: OTHER
Intervention: RAND 36-Item Health Survey 1.0
Description: Quality of life questionnaire

Intervention type: OTHER
Intervention: PREDICT-FFQ-v1
Description: Food frequency questionnaire

Intervention type: OTHER
Intervention: PREDICT-FFQ-v1
Description: Food frequency questionnaire

Intervention type: OTHER
Intervention: PREDICT-FFQ-v1
Description: Food frequency questionnaire
Study: NCT05885204

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy
Study: NCT06800560

Intervention type: OTHER
Intervention: PREDICT-FFQ-v1
Description: Food frequency questionnaire
Study: NCT06801665

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FMT+QL1706+Bevacizumab+XELOX
Description: Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.
Study: NCT06800365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor
Description: The FreeStyle Libre Pro sensor is a device whereby a sensor is inserted into subcutaneous tissue (upper arm) and measures the interstitial blood glucose which is then available for later download. It comes pre-calibrated meaning that no fingerstick glucose monitoring is required to improve accuracy of the sensor.
Study: NCT06801431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Individuals will receive a 10-day course of daily, 30-minute sessions of transcutaneous spinal cord stimulation to the thoracolumbar spine cord using the Chattanooga Mobile 2 Stim Device. These sessions will be conducted in the morning before bowel care and therapy. Cathode pads will be placed between the T10 and T11 spinous processes and the T12 and L1 spinous processes. Anode pads will be placed over the iliac crests. Stimulation will consist of 1 millisecond duration, biphasic pulses, at 30 Hertz frequency. The intensity of the current, will be adjusted to be suprasensory and sub-motor, and no more than 140 milli-amperes.
Study: NCT06801392

Intervention type: PROCEDURE
Intervention: pulsed-field ablation
Description: PVI + PW ablation

Intervention type: PROCEDURE
Intervention: pulsed-field ablation
Description: PVI + PW ablation

Intervention type: PROCEDURE
Intervention: pulsed-field ablation
Description: PVI + PW ablation
Study: NCT05582018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioTraceIO 360
Description: Use of the device for planning, monitoring and assessment of liver tissue ablations
Study: NCT05044819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral Cannabidiol solution 100 mg/mL
Study: NCT05786131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culprit-lesion revascularization
Description: Percutaneous coronary intervention of culprit-lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culprit-lesion revascularization
Description: Percutaneous coronary intervention of culprit-lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-culprit-lesion revascularization
Description: Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
Study: NCT06413498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anitocabtagene Autoleucel
Description: A single infusion of CAR+ transduced autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Administered intravenously or subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Administered intravenously or subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Administered intravenously
Study: NCT06072586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535
Description: BDTX-1535 is an inhibitor of EGFR mutations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535
Description: BDTX-1535 is an inhibitor of EGFR mutations
Study: NCT05885204

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy

Intervention type: PROCEDURE
Intervention: Conventional laparoscopic radical cystectomy
Description: Conventional laparoscopic radical cystectomy
Study: NCT05211791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block anesthesia
Description: Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
Study: NCT06404827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horseback riding simulator
Description: Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy and Rehabilitation
Description: Routine Physiotherapy and Rehabilitation within a spesific programme
Study: NCT05211791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural anesthesia
Description: insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
Study: NCT06801392

Intervention type: PROCEDURE
Intervention: pulsed-field ablation
Description: PVI + PW ablation
Study: NCT06801067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SER-155
Description: SER-155 (Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated) is an experimental designed ecology of 16 unique, human-commensal bacterial strains encapsulated for oral administration and will be provided by Seres as an investigational drug
Study: NCT06404827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physiotherapy and Rehabilitation
Description: Routine Physiotherapy and Rehabilitation within a spesific programme
Study: NCT06196905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: i.v. infusion
Study: NCT05885555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Intravenous infusion, prepared from concentrate solution
Study: NCT06480734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: symptom-based scoring system (symptom-questionnaire, paper version)
Description: The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
Study: NCT06801691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention group
Description: Educational materials: Iodine Feedback Tool, lecture on the topic of iodine and health, booklet, exercises, group assignments and a webpage This is a pre/post intervention with no control group.
Study: NCT06800326

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRE Scan
Description: Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
Study: NCT04930016

Intervention type: BEHAVIORAL
Intervention: Quality of life diagnosis and therapy during the completed RCT DIQOL
Description: Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
Study: NCT04155112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric Mediterranean diet
Description: Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
Study: NCT06367608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial treatment
Description: The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
Study: NCT04801459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction
Description: In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
Study: NCT05305508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
Study: NCT05521906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)
Description: The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
Study: NCT04150042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Intravenous melphalan (to be given in conjunction with the other listed drugs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: Intravenous BCNU (to be given in conjunction with the other listed drugs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12B
Description: Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C (to be given in conjunction with the other listed drugs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Intravenous ethanol (to be given in conjunction with the other listed drugs).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cells
Description: After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
Study: NCT04801459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction
Description: In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
Study: NCT05758389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
Description: evaluate the efficacy and safety of immunotherapy combined with chemotherapy
Study: NCT05055518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-102 Capsules
Description: Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102.